Zhongxing Bio-Technology approves 2025 stock option incentive plan

Tianshui Zhongxing Bio-Technology (SZSE:002772) announced the approval and initial grant under its 2025 Stock Option Incentive Plan. The company's board of directors, at its sixteenth meeting on October 15, 2025, approved the initial grant of 11.5m stock options to 17 recipients at an exercise price of 6.87 yuan per share. This represents 80% of the total 14.375m options planned, covering 2.92% of the company's total share capital. The remaining 2.875m options are reserved.

The plan has a validity period of 60 months from the initial grant date, with waiting periods of 12, 24, and 36 months for the three tranches of options. Performance targets for 2025 include achieving an operating income of no less than 2.1bn yuan, or a non-recurring net profit growth of no less than 55% over 2024. Similar targets are set for 2026 and 2027.

The shareholders' meeting on October 15, 2025, also confirmed the eligibility of the incentive recipients and the exercise conditions. Shanghai Rongzheng Enterprise Consulting Services (Group) Co., Ltd. acted as the independent financial advisor for this transaction, confirming that all procedures complied with relevant regulations.